Summary
Sacituzumab Govitecan has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lung Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lung Cancer. ClinicalTrials.gov lists 8 registered trials linking Sacituzumab Govitecan to Lung Cancer: 3 are currently recruiting; 3 are active or not yet recruiting; 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT06431633). The largest enrolment is 515 participants (NCT01631552). Registration activity spans 2012 to 2026. The literature layer holds 9 publications for this pair: 4 Cochrane reviews and 5 clinical trial publications. Publication years run from 2023 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Lung Cancer ranks 465 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 76.5 (trials 26.5, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 3 recruiting, 3 active / not yet recruiting, 1 completed, 1 other |
| Linked publications | 9 (5 clinical trial publications, 4 Cochrane reviews) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BRCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. 2025 | recruiting | Phase 3 | 129 |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer 2023 | active, not recruiting | Phase 2 | 192 |
| NCT07393555 | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) 2026 | not yet recruiting | Phase 2 | 117 |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer 2026 | recruiting | Phase 2 | 35 |
| NCT06477419 | A Study of Sacituzumab Govitecan in People With Mesothelioma 2024 | recruiting | Phase 2 | 33 |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion 2021 | active, not recruiting | Phase 1 | 169 |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer 2012 | completed | PHASE1, PHASE2 | 515 |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) 2017 | terminated | PHASE1, PHASE2 | 314 |
Published literature
- Clinical trial publication First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyReck M, Patel JD, Gray JE et al. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 41173143
- Cochrane review TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomesAnsab M, Rath S, Alam U et al. · Critical reviews in oncology/hematology · 2026 · PMID 41443486
- Clinical trial publication Clinical pharmacokinetics and immunogenicity evaluation of a trophoblast cell surface antigen 2-targeted antibody-drug conjugate, FDA018, in patients with epithelial malignant solid tumorsCheng M, Li X, Li Y et al. · Drug metabolism and disposition: the biological fate of chemicals · 2025 · PMID 41076974
- Clinical trial publication The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab GovitecanRoisman LC, Mann S, Basel A et al. · Clinical lung cancer · 2025 · PMID 40064573
- Clinical trial publication Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03Dowlati A, Chiang AC, Cervantes A et al. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025 · PMID 39755168
- Cochrane review Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysisXu YX, Shen Q, Lu XF et al. · Frontiers in pharmacology · 2025 · PMID 41601958
- Cochrane review Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysisZhang Y, Chen J, Wang X et al. · Frontiers in oncology · 2025 · PMID 40626021
- Clinical trial publication Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyPaz-Ares LG, Juan-Vidal O, Mountzios GS et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · PMID 38843511
- Cochrane review TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)Parisi C, Mahjoubi L, Gazzah A et al. · Cancer treatment reviews · 2023 · PMID 37230055
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Sacituzumab Govitecan approved for Lung Cancer?
Sacituzumab Govitecan has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lung Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lung Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Sacituzumab Govitecan in clinical trials for Lung Cancer?
ClinicalTrials.gov lists 8 registered trials linking Sacituzumab Govitecan to Lung Cancer: 3 are currently recruiting; 3 are active or not yet recruiting; 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT06431633). The largest enrolment is 515 participants (NCT01631552). Registration activity spans 2012 to 2026.
What does the evidence show for Sacituzumab Govitecan in Lung Cancer?
Sacituzumab Govitecan has both completed registered trials and synthesis-level publications linked to Lung Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.